InvestorsHub Logo
icon url

DonShimoda

05/05/11 11:44 AM

#7700 RE: BTH #7695

Precisely, the biomarkers should allow ariad to target those pts who have mutations that are not likely to respond to Pfizer's Crizotinib. Thanks for clearing up any confusion.